Peptic-ulcer disease

Lancet

Volumn 360, Issue 9337, 2002, Pages 933-941

  Chan, Francis K L ^a   Leung, W K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTACID AGENT; ANTIULCER AGENT; BICARBONATE; BISMUTH; BISMUTH CITRATE; BISMUTH SALICYLATE; CELECOXIB; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; FAMOTIDINE; FURAZOLIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; LANSOPRAZOLE; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN; PROTON PUMP INHIBITOR; RANITIDINE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; ROFECOXIB; TETRACYCLINE; VIRULENCE FACTOR;

ABDOMINAL CRAMP; BACTERIAL VIRULENCE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DUODENUM ULCER; ENDOSCOPY; ENVIRONMENTAL FACTOR; GASTRODUODENAL ULCER; GASTROINTESTINAL TOXICITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITAL ADMISSION; HOST; HUMAN; METAPLASIA; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSTAGLANDIN SYNTHESIS INHIBITION; RISK FACTOR; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH ULCER; TREATMENT OUTCOME;

EID: 0037152074     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11030-0     Document Type: Conference Paper

References (105)

1. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1:1984;1311-1315.
2. Anon. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-69.
3. Anon. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter pylori Study Group. Gut 1997; 41: 8-13.
4. Kurata J.H. Epidemiology of peptic ulcer disease. Clin Gastroenterol. 13:1984;289.
5. Munnangi S. Time trends of physician visits and treatment patterns of peptic ulcer disease in the United States. Arch Intern Med. 157:1997;1489-1494.
6. Higham J., Kang J.Y., Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut. 50:2002;460-464.
7. Singh G., Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J Rheumatol. 26:(suppl 26):1999;18-24.
8. Wolfe M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 340:1999;1888-1899.
9. Chan F.K. Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gastroenterol Clin North Am. 30:2001;937-952.
10. Laine L., Hopkins R.J., Girardi L.S. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol. 93:1998;1409-1415.
11. El-Omar E.M., Penman I.D., Ardill J.E., Chittajallu R.S., Howie C., McColl K.E. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology. 109:1995;681-691.
12. Moss S.F., Legon S., Bishop A.E., Polak J.M., Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet. 340:1992;930-932.
13. Olbe L., Hamlet A., Dalenback J., Fandriks L. A mechanism by which Helicobacter pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology. 110:1996;1386-1394.
14. Levi S., Beardshall K., Haddad G., Playford R., Ghosh P., Calam J. Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet. 1:1989;1167-1168.
15. Beales I., Calam J., Post L., et al. Effect of transforming growth factor alpha and interleukin 8 on somatostatin release from canine fundic D cells. Gastroenterology. 112:1997;136-143.
16. Beales I., Blaser M.J., Srinivasan S., et al. Effect of Helicobacter pylori products and recombinant cytokines on gastrin release from cultured canine G cells. Gastroenterology. 113:1997;465-471.
17. Graham D.Y., Dore M.P. Perturbations in gastric physiology in Helicobacter pylori duodenal ulcer: are they all epiphenomena? Helicobacter. 2:(suppl 1):1997;44-49.
18. Wyatt J.I., Rathbone B.J., Dixon M.F., Heatley R.V. Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis. J Clin Pathol. 40:1987;841-848.
19. Savarino V., Mela G.S., Zentilin P., et al. 24-hour gastric pH and extent of duodenal gastric metaplasia in Helicobacter pylori-positive patients. Gastroenterology. 113:1997;741-745.
20. Hogan D.L., Rapier R.C., Dreilinger A., et al. Duodenal bicarbonate secretion: eradication of Helicobacter pylori and duodenal structure and function in humans. Gastroenterology. 110:1996;705-716.
21. Isenberg J.I., Selling J.A., Hogan D.L., et al. Impaired proximal duodenal mucosal bicarbonate secretion in patients with duodenal ulcer. N Engl J Med. 316:1987;374-379.
22. Fandriks L., von Bothmer C., Johansson B., Holm M., Bolin I., Pettersson A. Water extract of Helicobacter pylori inhibits duodenal mucosal alkaline secretion in anesthetized rats. Gastroenterology. 113:1997;1570-1575.
23. Covacci A., Censini S., Bugnoli M., et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA. 90:1993;5791-5795.
24. Censini S., Lange C., Xiang Z., et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA. 93:1996;14648-14653.
25. Yamaoka Y., Kita M., Kodama T., Sawai N., Imanishi J. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology. 110:1996;1744-1752.
26. Segal E.D., Cha J., Lo J., Falkow S., Tompkins L.S. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci USA. 96:1999;14559-14564.
27. Odenbreit S., Puls J., Sedlmaier B., Gerland E., Fischer W., Haas R. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science. 287:2000;1497-1500.
28. Higashi H., Tsutsumi R., Muto S., et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori cagA protein. Science. 295:2002;683-686.
29. Atherton J.C., Peek R.M. Jr, Tham K.T., et al. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology. 112:1997;92-99.
30. Graham D.Y., Yamaoka Y. Disease-specific Helicobacter pylori virulence factors: the unfulfilled promise. Helicobacter. 5:(suppl 1):2000;3-9.
31. Gerhard M., Lehn N., Neumayer N., et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci USA. 96:1999;12778-12783.
32. Mizushima T., Sugiyama T., Komatsu Y., et al. Clinical relevance of the babA2 genotype of Helicobacter pylori in Japanese clinical isolates. J Clin Microbiol. 39:2001;2463-2465.
33. Schrager J., Spink R., Mitra S. The antrum in patients with duodenal and gastric ulcers. Gut. 8:1967;497-508.
34. Faber K. Chronic gastritis: Its relation to achylia and ulcer. Lancet. 2:1927;902-907.
35. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:2001;784-789.
36. Logan R.P., Walker M.M., Misiewicz J.J., et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut. 36:1995;12-16.
37. Meining A., Kiel G., Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther. 12:1998;735-740.
38. Graham D.Y. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: A model. Gastroenterology. 113:1997;1983-1991.
39. El-Omar E.M., Carrington M., Chow W.H., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 404:2000;398-402.
40. Van Zanten S.J.O.V., Dixon M.F., Lee A. The gastric transitional zones: neglected links between gastroduodenal pathology and helicobacter ecology. Gastroenterology. 116:1999;1217-1229.
41. Borody T.J., Cole P., Noonan S., et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust. 151:1989;431-435.
42. Lind T., Veldhuyzen van Zanten S., Unge P., et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1:1996;138-144.
43. Lind T., Megraud F., Unge P., et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology. 116:1999;248-253.
44. Sung J.J., Chan F.K., Wu J.C., et al. One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. Aliment Pharmacol Ther. 13:1999;1079-1084.
45. Misiewicz J.J., Harris A.W., Bardhan K.D., et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Gut. 41:1997;735-739.
46. Frevel M., Daake H., Janisch H.D., et al. Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens. Aliment Pharmacol Ther. 14:2000;1151-1157.
47. Megraud F., Roberts P., Williamson R. Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter. 5:2000;222-226.
48. Osato M.S., Reddy R., Reddy S.G., et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med. 161:2001;1217-1220.
49. Versalovic J., Shortbridge D., Kibler K., et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother. 40:1996;477-480.
50. Graham D.Y. Therapy for Helicobacter pylori: Current status and issues. Gastroenterology. 118:2000;1-8.
51. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht 2-2000Consensus Report. Aliment Pharmacol Ther. 16:2002;167-180.
52. Vaira D., Vakil N., Menegatti M., et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med. 136:2002;280-287.
53. Leung W.K., Graham D.Y. Rescue Therapy for Helicobacter pylori. Curr Treat Options Gastroenterol. 5:2002;133-138.
54. Malekzadeh R., Ansari R., Vahedi H., et al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther. 14:2000;299-303.
55. Perri F., Festa V., Clemente R., et al. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 96:2001;58-62.
56. Davenport H.W. Gastric mucosal hemorrhage in dogs. Effects of acid, aspirin, and alcohol. Gastroenterology. 56:1969;439-449.
57. Fromm D. How do non-steroidal anti-inflammatory drugs affect gastric mucosal defenses? Clin Invest Med. 10:1987;251-258.
58. Kelly J.P., Kaufman D.W., Jurgelon J.M., Sheehan J., Koff R.S., Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 348:1996;1413-1416.
59. Lichtenberger L.M., Wang Z.M., Romero J.J., et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med. 1:1995;154-158.
60. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 231:1971;232-235.
61. Whittle B.J. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology. 80:1981;94-98.
62. Rainsford K.D., Willis C. Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production. Dig Dis Sci. 27:1982;624-635.
63. Wallace J.L. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology. 112:1997;1000-1016.
64. Langenbach R., Morham S.G., Tiano H.F., et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 83:1995;483-492.
65. Elliott S.N., McKnight W., Cirino G., Wallace J.L. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 109:1995;524-530.
66. Wallace J.L., Keenan C.M., Granger D.N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol. 259:1990;462-467.
67. Appleyard C.B., McCafferty D.M., Tigley A.W., Swain M.G., Wallace J.L. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol. 270:1996;42-48.
68. Rainsford K.D. Microvascular injury during gastric damage by anti-inflammatory drugs in pigs and rats. Agents Actions. 13:1983;457-460.
69. Andrews F.J., Malcontenti-Wilson C., O'Brien P.E. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. Am J Physiol. 266:1994;657-664.
70. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M.B., Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 107:1994;173-179.
71. Vaananen P.M., Keenan C.M., Grisham M.B., Wallace J.L. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation. 16:1992;227-240.
72. Wallace J.L., McKnight G.W. The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. Gastroenterology. 99:1990;295-304.
73. Green F.W. Jr, Kaplan M.M., Curtis L.E., Levine P.H. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology. 74:1978;38-43.
74. Schmassmann A., Tarnawski A., Peskar B.M., et al. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: interaction with indomethacin. Am J Physiol. 268:1995;276-285.
75. Larkai E.N., Smith J.L., Lidsky M.D., Graham D.Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 82:1987;1153-1158.
76. Chan F.K., Sung J.Y., Ching J.Y., et al. Randomised trial of low-dose misoprostol and naproxen versus nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 15:2001;19-24.
77. Rostom A., Wells G., Tugwell P., Welch V., Dube C., McGowan J. Prevention of NSAID-induced gastroduodenal ulcers (Cochrane Review). Cochrane Database Syst Rev. 4:2000;CD002296.
78. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 123:1995;241-249.
79. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med. 334:1996;1435-1439.
80. Hudson N., Taha A.S., Russell R.I., et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 112:1997;1817-1822.
81. Yeomans N.D., Tulassay Z., Juhasz L., et al. Omeprazole compared with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 338:1998;719-726.
82. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 338:1998;727-734.
83. Graham D.Y., Agrawal N.M., Campbell D.R., et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol versus lansoprazole. Arch Intern Med. 162:2002;169-175.
84. Fu J.Y., Masferrer J.L., Seibert K., Raz A., Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 265:1990;16737-16740.
85. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528.
86. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA. 284:2000;1247-1255.
87. US Food and Drug Administration. Statistical review briefing document for the advisory committee. www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_04_stats.doc(accessed Sept 3, 2002).
88. Wallace J.L., McKnight W., Reuter B.K., Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 119:2000;706-714.
89. Mizuno H., Sakamoto C., Matsuda K., et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 112:1997;387-397.
90. To K.F., Chan F.K., Cheng A.S., Lee T.L., Ng Y.P., Sung J.Y. Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer. Aliment Pharmacol Ther. 15:2001;25-34.
91. Labenz J., Tillenburg B., Peitz U., et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology. 110:1996;725-732.
92. Laine L., Cominelli F., Sloane R., Casini-Raggi V., Marin-Sorensen M., Weinstein W.M. Interaction of NSAIDs and Helicobacter pylori on gastroduodenal injury and prostaglandin production: a controlled double-blind trial. Aliment Pharmacol Ther. 9:1995;127-135.
93. Hawkey C.J., Tulassay Z., Szczepanski L., et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet. 352:1998;1016-1021.
94. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 344:2001;967-973.
95. Taha A.S., Danhill S., Morran C., et al. Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug users. Gastroenterology. 116:1999;1-7.
96. Konturek J.W., Dembinski A., Konturek S.J., Stachura J., Domschke W. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology. 114:1998;245-255.
97. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 359:2002;14-22.
98. Chan F.K., Sung J.Y., Chung S.C., et al. Randomised trial of eradication of Helicobacter pylori before starting non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 350:1997;975-979.
99. Chan F.K., To K.F., Wu J.C., et al. Eradication of -Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 359:2002;9-13.
100. Griffin M.R., Piper J.M., Daugherty J.R., et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 114:1991;257-263.
101. Gabriel S.E., Jaakkimainen L., Bombardier C. Risks for serious gastrointestinal complications related to the use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med. 115:1991;787-796.
102. Jyotheeswaran S., Shah A.N., Jin H.O., Potter G.D., Ona F.V., Chey W.Y. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol. 93:1998;574-578.
103. Nishikawa K., Sugiyama T., Kato M., et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol. 12:2000;635-640.
104. Chan H.L., Wu J.C., Chan F.K., et al. Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. Gastrointest Endosc. 53:2001;438-442.
105. Graham D.Y. Large US clinical trials report a high proportion of H pylori negative duodenal ulcers at study entry as well as a high recurrence rate after cure of the infection: Have we all been wrong? Gastroenterology. 114:1998;17.